Inivata to Present at AACR Annual Meeting 2017
Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, today announces the presentation of new data at the AACR Annual Meeting 2017 in Washington, USA.
The data, entitled “Comparison of enhanced Tagged-Amplicon Sequencing and digital PCR for circulating tumor DNA analysis in advanced breast cancer”, will be presented on Monday 3 April from 1:00pm – 5:00pm at the Convention Center. The poster will present the results of a new study showing ctDNA analysis using Inivata’s InVisionTM platform and Digital PCR (dPCR) have very a high concordance in mutation detection in patients with advanced breast cancer.
Clive Morris, Chief Medical Officer of Inivata, said:
“These results add to our growing body of evidence for the clinical utility of our InVisionTM platform across a number of cancer types. While we have recently announced the results of a first study of the use of a ctDNA liquid biopsy in guiding treatment decisions and delivering better patient outcomes in lung cancer patients, here we explore the utility of ctDNA in breast cancer. These data demonstrate that while our InVision platform has strong concordance with dPCR in breast cancer patients, it also yields more clinically useful biomarker information through a broad panel approach over individual mutational analysis.”
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.